Scottish Terriers are compact, wire-coated terriers with an outsized disease burden for their size. Two conditions in particular make Scottie health management genuinely different from other small terriers: a bladder cancer rate that is among the most extreme breed-specific cancer predispositions documented in veterinary medicine, and a von Willebrand disease type III prevalence that affects how owners should approach even routine supplementation decisions. Understanding both changes the calculus significantly.

Scottie cramp

Scottie cramp is a breed-specific episodic movement disorder caused by a serotonin metabolism abnormality — specifically a defect in serotonin synthesis or availability at the spinal cord level that disrupts motor pathway function during periods of high serotonergic demand. Clinically it presents as episodic hypertonicity and abnormal limb movements triggered by exercise, excitement, or stress. Dogs may stumble, fall, or move in an exaggerated gait during episodes, then recover fully within minutes.

The condition is not painful and does not cause lasting neurological damage. Episodes are often mild enough that owners mistake them for clumsiness. There is no supplement intervention with documented efficacy for Scottie cramp. The serotonin metabolism basis of the condition has led to investigation of vitamin B6 (a cofactor in serotonin synthesis) and methysergide in research settings, but neither is a standard treatment. Management is primarily about avoiding the triggers that precipitate episodes: limiting intense exercise, managing excitement, and reducing stress events where possible.

Transitional cell carcinoma (bladder cancer)

This is the most clinically significant finding in Scottie health epidemiology. Scottish Terriers develop transitional cell carcinoma (TCC) of the bladder at 18 to 20 times the rate seen in mixed-breed dogs — the most extreme breed-specific cancer predisposition of this type documented in veterinary oncology. TCC in dogs is an aggressive urothelial malignancy that most commonly arises at the trigone region of the bladder, where it is surgically inaccessible, making this a condition where prevention and early detection carry particular weight.

Risk factors in Scotties appear to include metabolic carcinogen activation pathways involving aromatic amines — the same metabolic variation that increases TCC risk in humans. Exposure to lawn herbicides (particularly phenoxy acetic acid herbicides) and flea dip chemicals with organophosphate content has been associated with increased TCC incidence in this breed in epidemiological studies.

From a supplement standpoint: No supplement prevents TCC in Scotties, and no supplement should be presented as doing so. What is appropriate: omega-3 EPA+DHA at therapeutic doses for general immune modulation and anti-inflammatory support — omega-3 is a standard component of veterinary oncology nutritional protocols. Adequate hydration is mechanistically relevant because dilute urine reduces carcinogen contact time with urothelial cells; wet food and water fountains are more impactful than any specific supplement. Early detection matters: hematuria (blood in urine), dysuria, or pollakiuria in a Scottie warrants prompt imaging and urine cytology.

Von Willebrand disease type III

Scottish Terriers carry von Willebrand disease type III — the most severe form, characterized by near-complete absence of vWF protein and severely impaired primary hemostasis. Unlike vWD type I (partial deficiency, common in Dobermans) or type II (abnormal multimers, common in German Shorthaired Pointers), type III vWD in Scotties results in spontaneous bleeding risk, not just surgical risk. Affected dogs can bleed from minor trauma or even spontaneously into joints and body cavities.

DNA testing identifies affected, carrier, and clear status. The supplement implication is significant: any supplement with meaningful anti-platelet or anti-coagulant activity should be used with extreme caution or avoided in vWD-affected Scotties. High-dose omega-3 (above 20 mg EPA+DHA per pound of body weight) has measurable anti-platelet effects and should be discussed with the veterinarian before starting in a vWD-affected dog. Vitamin E at high doses similarly prolongs bleeding time. The therapeutic dose approach that is appropriate for a healthy dog of the same size requires modification in the context of type III vWD.

Allergic skin disease

Scotties have elevated atopic dermatitis rates consistent with terrier breeds generally. Environmental allergens drive the classic pattern: paw licking, facial rubbing, recurring ear infections, and interdigital furunculosis. Quercetin's mast cell stabilization and anti-histamine properties are appropriate here, as are omega-3 fatty acids for barrier restoration and inflammatory cytokine reduction — with the vWD caveats above governing dose in affected dogs.

The Scottish Terrier supplement protocol

• Omega-3 EPA+DHA — for allergy support, immune modulation, and as part of general cancer-risk management. Dose conservatively in vWD-affected dogs; discuss therapeutic dosing with the veterinarian for unaffected or carrier dogs
• Quercetin + bromelain — for atopic dermatitis management; no coagulation concerns at standard doses
• Probiotics — gut-immune calibration; relevant for immune baseline support
• Urinary hydration — wet food or water additives to maintain dilute urine; the single most evidence-informed practical measure for reducing urothelial carcinogen exposure
• Avoid without veterinary guidance in vWD-affected dogs: high-dose fish oil, high-dose vitamin E, ginkgo, turmeric at high doses, garlic

vWD DNA status should be confirmed before finalizing any supplement protocol. The treating veterinarian's input is essential given the coagulation context.

Related: bladder health supplement guide · cancer supplement guide · skin supplement guide · allergy supplement · omega-3 for dogs.